Pharmaceutical - Antibiotics and Infectious diseases


Popular Filters

201 to 220 of 220 results

Licensing deal for Basilea in sight


The completion of the pneumonia data audit and confirmation of the timeline for Switzerland-based Basilea’s…

Antibiotics and Infectious diseasesBasilea PharmaceuticaceftobiproleDermatologicalsLicensingPharmaceuticalResearchToctino

Astellas pulls out of deal with Theravance


Japanese drug major Astellas Pharma (TYO: 4503) says it has exercised its right to terminate the global…

Antibiotics and Infectious diseasesAstellas PharmaLicensingPharmaceuticalTheravanceVibativ

European Medicines Agency releases adverse reaction report


European Ombudsman Nikiforos Diamandouros has welcomed the European Medicines Agency's release of adverse…

Antibiotics and Infectious diseasesEuropePharmaceuticalRegulation

Astellas and Optimer’s C. difficile drug cleared in Europe


Following an earlier positive recommendation from a European Medicines Agency advisory panel (The Pharma…

Antibiotics and Infectious diseasesAstellas PharmaDificidDificlirEuropeOptimer PharmaceuticalsPharmaceuticalRegulation

TaiGen gets global nemonoxacin rights


Taiwan’s TaiGen Biotechnology has reached a deal with Ireland-headquartered Warner Chilcott (Nasdaq:…

Antibiotics and Infectious diseasesBiotechnologyLicensingnemonoxacinPharmaceuticalTaiGen BiotecnologyWarner Chilcott

Backing for Japanese approval of Regnite, Ranmark and Cancidas


USA-based XenoPort (Nasdaq: XNPT) saw its shares rise 3% to $4.73 on Friday, when the company said it…

Antibiotics and Infectious diseasesAsia-PacificCancidasDaiichi SankyodenosumabHorizantMerck & CoOncologyPharmaceuticalRegniteRegulationXenoPort

New compound defeats drug-resistant bacteria


Bacteria can use efflux pumps to rid themselves of antibiotics, becoming drug-resistant until newer antibiotics…

Antibiotics and Infectious diseasesMPEX PharmaceuticalsPharmaceuticalResearch

World antibacterials market to grow to $43.8 billion in 2016, says Visiongain


World revenues for antibacterial drugs will reach $43.81 billion in 2016. Between 2010 and 2022, the…

Antibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceutical

Key hospital-infections markets set to grow to over $4 billion in 2020; report


Despite market constraints that include intensified competition, generic erosion and an increasingly…

Antibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceutical

EU Commission unveils 12 concrete actions against antimicrobial resistance for the next five years


With about 25,000 patients dying per year in the European Union from infections caused by drug resistant…

Antibiotics and Infectious diseasesEuropePharmaceuticalRegulationResearch

Sanofi Pasteur and CureVac collaborate on a $33.1 million project on vaccines for infectious diseases


Germany’s CureVac says it has signed several agreements with Sanofi Pasteur, the vaccines division…

Antibiotics and Infectious diseasesBiotechnologyCureVacLicensingPharmaceuticalResearchSanofiSanofi PasteurVaccines

US hospital pharmacy and therapeutics committees decision-making process for antibiotics and antifungal therapies


In addition to managing the hospital’s anti-infective formulary, hospital pharmacy and therapeutics…

Antibiotics and Infectious diseasesGenericsMarkets & MarketingNorth AmericaPharmaceutical

US FDA should require Black Box warning for Pfizer’s antibiotic Tygacil, says Public Citizen


US advocacy group Public Citizen has sent a petition to the Food and Drug Administration calling on the…

Antibiotics and Infectious diseasesNorth AmericaPfizerPharmaceuticalRegulationTygacil

EFPIA supports a new R&D model to tackle antimicrobial resistance


A vote of the European Parliament’s Health Committee on the threat posed by antimicrobial resistance,…

Antibiotics and Infectious diseasesEuropePharmaceuticalPoliticsResearch

Eli Lilly pulls sepsis drug Xigris off all markets, due to lack of efficacy


US drug major Eli Lilly (NYSE: LLY) revealed yesterday that it is withdrawing its Xigris (drotrecogin…

Antibiotics and Infectious diseasesEli LillyMarkets & MarketingPharmaceuticalResearchXigris

GlaxoSmithKline warned by US FDA over cGMP violations at UK plant; positive malaria vaccine news


UK pharma giant GlaxoSmithKline ILSE: GSK) has received a warning letter from the US Food and Drug Administration…

Antibiotics and Infectious diseasesGlaxoSmithKlinePharmaceuticalRegulationResearchVaccines

AstraZeneca and Forest initiate Ph III trials of CAZ-AVI


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and USA-based Forest Laboratories (NYSE: FRX) said this…

Antibiotics and Infectious diseasesAstraZenecaavibactamCeftazidimeForest LaboratoriesPharmaceuticalResearch

Inconclusive Ph III results for Pfizer’s Vfend and Eraxis combo in fungal infections


There was disappointing news for global drugs behemoth Pfizer (NYSE: PFE) last Friday, when the company…

Antibiotics and Infectious diseasesEraxisPfizerPharmaceuticalResearchVfend

More news from EMA/CHMP September meeting


Following its meetings last week, the European Medicines Agency’s Committee for Medicinal Products…

Anti-viralsAntibiotics and Infectious diseasesAstellas PharmaCelgeneDificidDificlirEuropeEvipleraGilead SciencesOncologyPharmaceuticalRegulationRevlimidUCBVimpat

201 to 220 of 220 results

Back to top